Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Treasury Shares (2016 - 2025)

Neurocrine Biosciences' Treasury Shares history spans 15 years, with the latest figure at $2.6 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 8.33% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $2.6 million, up 8.33%, while the annual FY2025 figure was $2.6 million, 8.33% up from the prior year.
  • Treasury Shares reached $2.6 million in Q4 2025 per NBIX's latest filing, up from $1.5 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $2.6 million in Q4 2025 to a low of $500000.0 in Q4 2022.
  • Average Treasury Shares over 5 years is $1.8 million, with a median of $1.8 million recorded in 2021.
  • Peak YoY movement for Treasury Shares: tumbled 75.0% in 2022, then skyrocketed 380.0% in 2023.
  • A 5-year view of Treasury Shares shows it stood at $2.0 million in 2021, then crashed by 75.0% to $500000.0 in 2022, then surged by 380.0% to $2.4 million in 2023, then changed by 0.0% to $2.4 million in 2024, then increased by 8.33% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Treasury Shares are $2.6 million (Q4 2025), $1.5 million (Q3 2025), and $1.5 million (Q2 2025).